Anthony S Stein, Monzr M Al Malki, Dongyun Yang, Joycelynne M Palmer, Ni-Chun Tsai, Ibrahim Aldoss, Haris Ali, Ahmed Aribi, Andrew Artz, Savita Dandapani, Len Farol, Susanta Hui, An Liu, Ryotaro Nakamura, Vinod Pullarkat, Eric Radany, Joseph Rosenthal, Amandeep Salhotra, James F Sanchez, Ricardo Spielberger, Guido Marcucci, Stephen J Forman, Jeffrey Wong
Graft-versus-host disease (GVHD) has remained the main cause of post-transplantation mortality and morbidity after allogeneic hematopoietic cell transplantation (alloHCT), adding significant economic burden and affecting quality of life. It would be desirable to reduce the rate of GVHD among patients in complete remission (CR) without increasing the risk of relapse. In this study, we have tested a novel conditioning regimen of total marrow and lymphoid irradiation (TMLI) at 2000 cGy, together with post-transplantation cyclophosphamide (PTCy) for patients with acute myeloid leukemia in first or second CR, to attenuate the risk of chronic GVHD by using PTCy, while using escalated targeted radiation conditioning before allografting to offset the possible increased risk of relapse...
April 6, 2022: Transplantation and cellular therapy